



期刊导读

6卷11期 2012年6月 [最新]



期刊存档

期刊存档

期刊订阅



在线订阅



邮件订阅



RSS

作者中心



晋升信息



作者查稿



写作技巧



投稿方式



作者指南



期刊服务



建议我们



会员服务



广告合作



继续教育

您的位置: [首页](#)>> [文章摘要](#)

细胞因子诱导杀伤细胞治疗肿瘤的临床免疫学评价体系

庞云, 王子健, 韩润林, 竺青

庞云、韩润林, 呼和浩特 内蒙古农业大学血浆脂蛋白免疫学研究中心, 010018; 庞云、王子健、韩润林、竺青, 北京京蒙高科干细胞技术有限公司, 内蒙古自治区干细胞医学工程技术研究中心; 王子健、竺青, 中国科学院生物物理研究所

摘要: 细胞治疗作为抗肿瘤的新型模式已在临床广泛开展。细胞因子诱导杀伤(cytokine-induced killer, CIK)细胞具有较强增殖、杀伤和提高机体免疫反应的作用, 其治疗技术成为细胞治疗领域的先导。CIK细胞临床应用研究的进一步深入迫切需要一套综合、系统的临床评价体系。临床免疫学检测对于CIK细胞治疗技术的改进和完善具有重要的指导意义, 也为客观评估这一技术的有效性和安全性以及制定医疗规范标准提供必要的参考依据。恶性肿瘤升为人类第一死亡原因, 寻找有效的抗肿瘤疗法是当前临床研究的重要课题。由于很多患者不能承受常规手术和放疗化疗治疗或对这些方法无效, 利用免疫机制清除肿瘤、提高生存期和生活质量成为一个令人期待的理想途径。然而, 恶性肿瘤细胞通常抑制免疫细胞对其进行攻击的能力, 机体免疫系统故而受到不同程度损害, CIK细胞含量常低于正常人的1%~5%, 造成免疫低下, 无法达到有效杀伤肿瘤细胞的临床效果。

关键词: 细胞

[评论](#) [收藏](#) [全文阅读: FullText | PDF](#)

文献标引: 庞云, 王子健, 韩润林, 竺青. 细胞因子诱导杀伤细胞治疗肿瘤的临床免疫学评价体系[J/CD]. 中华临床医师杂志: 电子版, 2011, 5(8): 2368-2373.

参考文献:

- [1] Sentman CL, Barber MA, Barber A, et al. NK cell receptors as tools in cancer immunotherapy. *Adv Cancer Res*, 2006, 95: 249-292. [[PubMed](#)]
- [2] Schmidt-Wolf IG, Negrin RS, Kiem HP, et al. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. *J Exp Med*, 1991, 174: 139-149. [[PubMed](#)]
- [3] Wang QJ, Wang H, Pan K, et al. Comparative study on anti-tumor immune response of autologous cytokine-induced killer (CIK) cells, dendritic cells-CIK (DC-CIK), and semi-allogeneic DC-CIK. *Chin J Cancer*, 2010, 29: 641-648. [[PubMed](#)]
- [4] Schmidt-Wolf IG, Finke S, Trojaneck B, et al. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. *Br J Cancer*, 1999, 81: 1009-1016. [[PubMed](#)]
- [5] Olioso P, Giancola R, Di Riti M, et al. Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. *Hematol Oncol*, 2009, 27: 130-139. [[PubMed](#)]
- [6] Mehta BA, Schmidt-Wolf IG, Weissman IL, et al. Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+ CD56+ killer cells. *Blood*, 1995, 86: 3493-3499. [[PubMed](#)]
- [7] Verneris MR, Kornacker M, Mailänder V, et al. Resistance of ex vivo expanded CD3+CD56+ T cells to Fas-mediated apoptosis. *Cancer Immunol Immunother*, 2000, 49: 335-345. [[PubMed](#)]
- [8] Marin V, Pizzitola I, Agostoni V, et al. Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors. *Haematologica*, 2010, 95: 2144-2152. [[PubMed](#)]
- [9] Zhou QM, Wu PH, Zhao M, et al. Short-term curative efficacy of cytokine-induced killer cells combined micro-invasive treatments on hepatocellular carcinoma. *Ai Zheng*, 2006, 25: 1414-1418. [[PubMed](#)]
- [10] Wu C, Jiang J, Shi L, et al. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. *Anticancer Res*, 2008, 28: 3997-4002. [[PubMed](#)]
- [11] Zhao G, Huang Y, Ye L, et al. Therapeutic efficacy of Traditional Vein Chemotherapy and Bronchial Arterial Infusion Combining with CIKs on III Stage Non-small Cell Lung Cancer. *Zhongguo Fei Ai Za Zhi*, 2009, 12: 1000-1004. [[PubMed](#)]
- [12] Helms MW, Prescher JA, Cao YA, et al. IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy. *Cancer Immunol Immunother*, 2010, 59: 1325-1334. [[PubMed](#)]
- [13] Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer*, 2009, 45: 228-247. [[PubMed](#)]

- [14] Schneider J. Detection of lung cancer in silicosis patients using a tumor-marker panel. *Cancer Biomark*, 2010, 6: 137-148. [\[PubMed\]](#)
- [15] Saloustros E, Mavroudis D. Cytokeratin 19-positive circulating tumor cells in early breast cancer prognosis. *Future Oncol*, 2010, 6: 209-219. [\[PubMed\]](#)
- [16] Bryniarski P, Paradysz A, Fryczkowski M. PSA mass as a marker of prostate cancer progression after radical prostatectomy. *Med Sci Monit*, 2011, 17: CR104-109. [\[PubMed\]](#)
- [17] Cioffi M, Fratta M, De Lucia D, et al. A retrospective study of the serum CEA, AFP, TPA and ferritin values in 500 patients with chronic liver diseases. *Arch Monaldi Mal Torace*, 1990, 45: 159-165. [\[PubMed\]](#)
- [18] Molina R, Augé JM, Escudero JM, et al. Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value. *Tumour Biol*, 2010, 31: 171-180. [\[PubMed\]](#)
- [19] Nicolini A, Ferrari P, Duffy MJ, et al. Intensive risk-adjusted follow-up with the CEA, TPA, CA19.9, and CA72.4 tumor marker panel and abdominal ultrasonography to diagnose operable colorectal cancer recurrences: effect on survival. *Arch Surg*, 2010, 145: 1177-1183. [\[PubMed\]](#)
- [20] Villanacci V, Cestari R, Giulini S, et al. Immunocytochemical assessment of p53 protein to detect malignancy in increased cell-yield brush cytology from the biliopancreatic tree. *Dig Dis Sci*, 2009, 54: 789-792. [\[PubMed\]](#)
- [21] van de Lande J, Davelaar EM, von Mensdorff-Pouilly S, et al. SCC-Ag, lymph node metastases and sentinel node procedure in early stage squamous cell cervical cancer. *Gynecol Oncol*, 2009, 112: 119-125. [\[PubMed\]](#)
- [22] Takahashi Y, Mai M. Significance of CA72-4 as a follow up of recurrent gastric cancer--comparison with CEA and CA19-9. *Gan To Kagaku Ryoho*, 1992, 19: 515-518. [\[PubMed\]](#)
- [23] Lau P, Chin JL, Pautler S, et al. NMP22 is predictive of recurrence in high-risk superficial bladder cancer patients. *Can Urol Assoc J*, 2009, 3: 454-458. [\[PubMed\]](#)
- [24] Ni XG, Bai XF, Mao YL, et al. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. *Eur J Surg Oncol*, 2005, 31: 164-169. [\[PubMed\]](#)
- [25] Huang WC, Wu D, Xie Z, et al. beta2-microglobulin is a signaling and growth-promoting factor for human prostate cancer bone metastasis. *Cancer Res*, 2006, 66: 9108-9116. [\[PubMed\]](#)
- [26] Huang C, Bei L, Liu T. The clinical value of tumor marker CA50 and CA242 in digestive tract cancer. *Zhongguo Yi Xue Ke Xue Yuan Xue Bao*, 1998, 20: 285-288. [\[PubMed\]](#)
- [27] Haas M, Laubender RP, Stieber P, et al. Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer. *Tumour Biol*, 2010, 31: 351-357. [\[PubMed\]](#)
- [28] Su X, Zhang L, Jin L, et al. Immunotherapy with cytokine-induced killer cells in metastatic renal cell carcinoma. *Cancer Biother Radiopharm*, 2010, 25: 465-470. [\[PubMed\]](#)
- [29] Weng DS, Zhou J, Zhou QM, et al. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas. *J Immunother*, 2008, 31: 63-71. [\[PubMed\]](#)
- [30] Moser M, Murphy KM. Dendritic cell regulation of TH1-TH2 development. *Nat Immunol*, 2000, 1: 199-205. [\[PubMed\]](#)
- [31] Shi M, Zhang B, Tang ZR, et al. Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma. *World J Gastroenterol*, 2004, 10: 1146-1151. [\[PubMed\]](#)
- [32] Wei XC, Zhai XH, Han XR, et al. Biological activity of DC-CIK cells and its effect against leukemia cells in vitro. *Zhongguo Shi Yan Xue Ye Xue Za Zhi*, 2008, 16: 1150-1153. [\[PubMed\]](#)
- [33] 田秀君, 史娟, 乌娜娜, 等. 肿瘤调节性T细胞与肿瘤免疫[J/CD]. *中华临床医师杂志: 电子版*, 2010, 4: 2205-2208.
- [34] Li H, Ren XB, Zhang P, et al. Dendritic cells reduce the number and function of CD4+CD25+ cells in cytokine-induced killer cells. *Zhonghua Yi Xue Za Zhi*, 2005, 85: 3134-3138. [\[PubMed\]](#)
- [35] 雷静, 钱旻, 吴芝莉, 等. 体外CIK细胞的细胞因子表达谱研究的初步探讨. *中国免疫学杂志*, 2005, 21: 589-593.
- [36] Miwa K, Shibayama N, Moriguchi T, et al. A rapid enzyme-linked immunosorbent assay with two modes of detection for measuring cytokine concentration. *J Clin Lab Anal*, 2009, 23: 40-44. [\[PubMed\]](#)
- [37] Ku i S, Rettinger E, Voss B, et al. Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantation. *Haematologica*, 2010, 95: 1579-1586. [\[PubMed\]](#)
- [38] von Zons P, Crowley-Nowick P, Friberg D, et al. Comparison of europium and chromium release assays: cytotoxicity in healthy individuals and patients with cervical carcinoma. *Clin Diagn Lab Immunol*, 1997, 4: 202-207. [\[PubMed\]](#)
- [39] 李慧, 岳欣, 安秀梅, 等. 不同输注途径对CIK细胞体内分布和抑瘤作用的影响. *免疫学杂志*, 2007, 23: 416-420.
- [40] Hong H, Yang Y, Zhang Y, et al. Non-invasive cell tracking in cancer and cancer therapy. *Curr Top Med Chem*, 2010, 10: 1237-1248. [\[PubMed\]](#)

烧伤患者的康复治疗

龙艺, 贾赤字. . 中华临床医师杂志: 电子版
2011;5(8):2320-2323 .

[摘要](#) [FullText](#) | [PDF](#) | [评论](#) | [收藏](#)

小儿单肺通气的麻醉

刘伟, 耿万明. . 中华临床医师杂志: 电子版
2011;5(8):2324-2327 .

[摘要](#) [FullText](#) | [PDF](#) | [评论](#) | [收藏](#)

双腔管法行单肺通气麻醉时临床常见的问题

王伶俐, 肖少华. . 中华临床医师杂志: 电子版
2011;5(8):2328-2329.

[摘要](#) [FullText](#) | [PDF](#) | [评论](#) | [收藏](#)

核转录因子红细胞系-2p45相关因子-2调控抗氧化酶表达与帕金森病

徐先结, 叶钦勇. . 中华临床医师杂志: 电子版
2011;5(8):2330-2334.

[摘要](#) [FullText](#) | [PDF](#) | [评论](#) | [收藏](#)

成套神经心理测验及其分测验在痴呆中的应用评价

刘园园, 肖世富. . 中华临床医师杂志: 电子版
2011;5(8):2335-2338 .

[摘要](#) [FullText](#) | [PDF](#) | [评论](#) | [收藏](#)

神经前体细胞与缺血性脑损伤

杨云凤, 吴碧华. . 中华临床医师杂志: 电子版
2011;5(8):2339-2342 .

[摘要](#) [FullText](#) | [PDF](#) | [评论](#) | [收藏](#)

抗病毒治疗在阻断艾滋病传播流行中的作用

臧春鹏, 汪宁. . 中华临床医师杂志: 电子版
2011;5(8):2343-2346.

[摘要](#) [FullText](#) | [PDF](#) | [评论](#) | [收藏](#)

T细胞免疫球蛋白黏蛋白分子3及其配体在慢性病毒感染中的作用研究进展

刘琼, 谢冬英. . 中华临床医师杂志: 电子版
2011;5(8):2347-2349.

[摘要](#) [FullText](#) | [PDF](#) | [评论](#) | [收藏](#)

中心动脉压的研究进展

汪正权, 梁雨露. . 中华临床医师杂志: 电子版
2011;5(8):2350-2352 .

[摘要](#) [FullText](#) | [PDF](#) | [评论](#) | [收藏](#)

间充质干细胞治疗缺血性心脏病的机制

侯婧, 吕安林, 燕学波, 刘博武, 黄炜, 李垚. . 中华临床医师杂志: 电子版
2011;5(8):2353-2356.

[摘要](#) [FullText](#) | [PDF](#) | [评论](#) | [收藏](#)

Th17细胞生物学功能及与心血管疾病关系的研究进展

崔瑶, 秦明照. . 中华临床医师杂志: 电子版
2011;5(8):2357-2359.

[摘要](#) [FullText](#) | [PDF](#) | [评论](#) | [收藏](#)

NOB1基因研究进展

贺孝文. . 中华临床医师杂志: 电子版
2011;5(8):2360-2363 .

[摘要](#) [FullText](#) | [PDF](#) | [评论](#) | [收藏](#)

脑高灌注综合征的新进展

王兴, 吴绮思, 肖占琴, 陈阳美. . 中华临床医师杂志: 电子版
2011;5(8):2364-2367.

[摘要](#) [FullText](#) | [PDF](#) | [评论](#) | [收藏](#)

细胞因子诱导杀伤细胞治疗肿瘤的临床免疫学评价体系

庞云, 王子健, 韩润林, 竺青. . 中华临床医师杂志: 电子版
2011;5(8):2368-2373 .

